Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Enoxaparin for the Prevention of Preeclampsia and Intrauterine Growth Restriction in Women With a History: A Randomized Trial

Groom, K.M.; McCowan, L.M.; Mackay, L.K.; Lee, A.C.; Said, J.M.; Kane, S.C.; Walker, S.P.; van Mens, T.E.; Hannan, N.J.; Tong, S.; Chamley, L.W.; Stone, P.R.; McLintock, C.Enoxaparin for Prevention of Preeclampsia and Intrauterine Growth Restriction Trial Investigator Group

doi: 10.1097/01.aoa.0000527019.09758.9d
Epidemiologic Reports Surveys

(Am J Obstet Gynecol. 2017;216(3):296.e1–296.e14)

Preeclampsia and intrauterine growth restriction (IUGR) are both placental diseases and major causes of perinatal and maternal morbidity and mortality. The most commonly used risk predictor for both IUGR and preeclampsia is obstetric history, and women are more significantly at risk if the condition occurred early in pregnancy and was severe. Previous studies have shown aspirin and calcium can significantly reduce the incidence of preeclampsia, and results from trials for heparin and low-molecular-weight-heparin (LMWH) have yielded conflicting results. This multicenter randomized controlled trial aimed to assess the use of LMWH for the prevention of small for gestational age (SGA) infants and preeclampsia in women with a history of these conditions.

Department of Obstetrics and Gynecology, University of Auckland, Auckland, New Zealand; National Women’s Health, Auckland City Hospital, Auckland, New Zealand

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved